These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 9191478)

  • 1. The acute coronary ischemic syndromes--the central role of thrombosis.
    Cairns JA
    Can J Cardiol; 1996 Oct; 12(10):901-7. PubMed ID: 9191478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic treatment of acute coronary syndromes.
    Théroux P
    Can J Cardiol; 1998 Aug; 14 Suppl E():6E-10E. PubMed ID: 9779026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombolytic, antithrombin, and antiplatelet treatment of acute coronary syndromes.
    Puma JA; Sketch MH
    J Am Osteopath Assoc; 2000 Nov; 100(11 Suppl):S8-12. PubMed ID: 11191119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chronic ischemic cardiopathy: antiplatelet agents and anticoagulants, new protocols for prevention and treatment].
    Melandri G; Semprini F; Cervi V; Candiotti N; Branzi A
    Cardiologia; 1994 Dec; 39(12 Suppl 1):347-52. PubMed ID: 7634295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. API expert consensus document on management of ischemic heart disease.
    Association of Physicians of India
    J Assoc Physicians India; 2006 Jun; 54():469-80. PubMed ID: 16909697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between thrombolysis in myocardial infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the randomized trial to evaluate the relative PROTECTion against post-PCI microvascular dysfunction and post-PCI ischemia among antiplatelet and antithrombotic agents-Thrombolysis In Myocardial Infarction 30 (PROTECT-TIMI 30).
    Gibson CM; Kirtane AJ; Morrow DA; Palabrica TM; Murphy SA; Stone PH; Scirica BM; Jennings LK; Herrmann HC; Cohen DJ; McCabe CH; Braunwald E;
    Am Heart J; 2006 Oct; 152(4):756-61. PubMed ID: 16996854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacologic therapy of acute coronary syndromes].
    Holm F; Aschermann M
    Cas Lek Cesk; 2003 Aug; 142(8):456-9. PubMed ID: 14626558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of cardiovascular events after acute coronary syndrome.
    Wallentin L
    Semin Vasc Med; 2005 Aug; 5(3):293-300. PubMed ID: 16123917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38.
    Wiviott SD; Braunwald E; Angiolillo DJ; Meisel S; Dalby AJ; Verheugt FW; Goodman SG; Corbalan R; Purdy DA; Murphy SA; McCabe CH; Antman EM;
    Circulation; 2008 Oct; 118(16):1626-36. PubMed ID: 18757948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Future perspectives on antithrombin and antiplatelet therapies: novel antiplatelet and antithrombin therapies.
    Kandzari DE
    Rev Cardiovasc Med; 2006; 7 Suppl 3():S43-52. PubMed ID: 17228270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New trials and therapies for acute myocardial infarction.
    Gumina RJ
    Med Clin North Am; 2007 Jul; 91(4):729-49; xii. PubMed ID: 17640545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current use of anti-hemostatics in ischemic cardiopathy].
    Bolao IG; Alegría E; Iglesias I; Velasco S; Fidalgo ML; Gómez JA; Huelmos A
    Rev Med Univ Navarra; 1990; 34(4):219-26. PubMed ID: 2152748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiplatelet drugs in cardiovascular prevention: coronary events: acute phase and secondary prevention.
    Prescrire Int; 2000 Jun; 9(47):83-5. PubMed ID: 11010749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognosis after acute coronary syndrome. Lack of difference according to the sex].
    Bounhoure JP; Farah B; Fajadet J; Marco J
    Bull Acad Natl Med; 2004; 188(3):383-97; discussion 397-9. PubMed ID: 15584651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolving antithrombotic treatment strategies for acute ST-elevation myocardial infarction.
    Kandzari DE
    Rev Cardiovasc Med; 2006; 7 Suppl 4():S29-37. PubMed ID: 17224888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
    Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E
    J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
    Toth PP
    Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiplatelet and antithrombin therapies in the acute coronary syndromes.
    Alexander JH; Harrington RA
    Curr Opin Cardiol; 1997 Jul; 12(4):427-37. PubMed ID: 9263656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of antiplatelet agents and anticoagulants for cardiovascular disease: current standards and best practices.
    Faxon DP
    Rev Cardiovasc Med; 2005; 6 Suppl 4():S3-14. PubMed ID: 17710074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Coronary thrombosis--an old concept in a new light].
    Baur HR
    Schweiz Rundsch Med Prax; 1992 Sep; 81(39):1147-51. PubMed ID: 1410998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.